N/A N=100 Rapid, Minimally-invasive Voluntary Adult Male Circumcision
Circumcision
Primary: Intraoperative Duration — 9.0; 22.6 Min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 A Randomized Controlled Trial of Open Surgical vs. Rapid, Minimally-invasive Voluntary Adult Male Circumcision
Circumcision
Primary: Intraoperative Duration — 22.6; 13.0; 25.0; 28.6 minutes
N/A N=200 A Randomized Controlled Trial of Open Surgical vs. Minimally-invasive Voluntary Adult Male Circumcision
Surgical Technique
Primary: Intraoperative Duration — 22.5; 12.8 Min
Phase 4 N=75 Unicirc vs Open Surgical Circumcision
Circumcision, Male
Primary: Time Elapsed From First Clamp (Surgical) or Start of Insertion of Bell (Unicirc) to Beginning of Wound Dressing — 12; 25 Minutes
N/A N=2,242 Uptake of Medical Male Circumcision Among Men With Sexually Transmitted Infections
HIV Infections · Sexually Transmitted Infections
Primary: Number of Male Clients Who Will Undergo Circumcision (Uptake of VMMC) — 8; 25; 13; 17 Participants — p=0.044
Phase 4 N=54 Unicirc Adolescent 12-15 Year Old Boys
Circumcision, Male
Primary: Intraoperative Duration — 9.5 minutes
N/A N=110 Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive
Male Circumcision
Primary: Time for Procedure — 9.0 Min
N/A N=1,093 Two-way Texting for VMMC Follow-up in Republic of South Africa
Voluntary Medical Male Circumcision
Primary: Cumulative Percentage of Patients With an Adverse Event (AE) (Moderate or Severe) on or Before Day 14 Visit — 2.3; 1.01 percentage of participants
N/A N=274 Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial
Circumcision, Male
Primary: Neonatal Salivary Cortisol Level — 0.63; 0.72; 1.14; 1.08 mcg/dL
N/A N=258 Dorsal Penile Nerve Block for Rigid Cystoscopy in Men
Pain
Primary: Visual Analog Scale (VAS) for Pain — 6; 4; 4 units on a scale
N/A N=82 Penile Length Maintenance Post-Prostatectomy
Prostate Cancer · Penile Diseases
Primary: Change in Penile Length — 0.3; 1.6 centimeters
Phase 3 N=37 Bladder Scan of Residual Urine With New Catheter
Urinary Incontinence
Primary: Mean Residual Urine Volume — 12.4; 9.4 mL
Phase 3 N=52 Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
Malignant Neoplasms of Male Genital Organs
Primary: Post-Operative Pain Medication Usage in Post Anesthesia Care Unit (PACU) — 13.0208; 15.1786 mg
N/A N=26 The Compartmental Biology of HIV in the Male Genital Tract
Human Immunodeficiency Virus · Virus Shedding
Primary: Semen Clearance (CL) of Tenofovir — 33.88; 51.21; 5.65 L/hr
N/A N=504 Condom Performance in a Longitudinal Enhanced Assessment of User Experiences
HIV
Primary: Sexual Pleasure Scale Score for Fitted Versus Standard Condoms — 71.52; 70.13 score on a scale — p=<0.05
N/A N=50 A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
Urinary Incontinence, Stress
Primary: Procedural Endpoint: Procedure Time From First Incision to Closing. — 61.8 minutes
N/A N=110 Penile Length Restoration in Men With Diabetes Mellitus, Type II
Diabetes Mellitus, Type 2 · Penile Diseases
Primary: Penile Length Change Between Baseline and Month 6 — 0; 0.5; 0.5; 0.8 Median change from baseline (cm)
Phase 2 N=100 YCFM (Youth Correctional Facilities Males)
Chlamydial Infection
Primary: Proportion of Participants Experiencing Treatment Failure After Treatment With Azithromycin for Uncomplicated Chlamydia Trachomatis (CT) in Males With and Without…
N/A N=1,181 Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Human Immunodeficiency Virus Infection · Sexually Transmitted Diseases
Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008
Phase 2 N=25 Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
Urinary Incontinence · Stress · Urination Disorders
Primary: Rate of Product-related, Biopsy Procedure-related, and Injection Procedure-related Adverse Events — 0; 2; 0; 12 events
N/A N=570 Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy
Varicocele
Primary: Recurrent Varicocele — 2; 16 participants
N/A N=59 Male External Catheters' Comparison of Comfort and Efficacy
Non-invasive Urine Output Management
Primary: Performance of the PureWick MEC Against an Established Comparator — 97.8; 90.7; 91.1; 85.2 Percentage of urine captured — p=0.04
Phase 3 N=32 PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue
Healthy
Primary: Prostate-specific Antigen (PSA) — 0.8; 0.9; 0.7; 0.4 ng/mL
N/A N=67 Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair
Hypospadias
Primary: Number of Participants With Urinary Tract Infection — 30; 22; 0; 0 Participants
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
Phase 4 N=610 Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery
Post-operative Urinary Retention
Primary: Number of Patients Who Undergo Postoperative Catheterization for Urinary Retention — 23; 25 Participants — p=.96
N/A N=345 Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination
Human Papillomavirus
Primary: Prevalence of Penile HPV Genotypes — 2.6; 0.7; 21.7; 11.6 percentage of participants
Phase 4 N=20 Randomized Trial of Ropivacaine & Bupivacaine for Inflatable Penile Prosthesis
Erectile Dysfunction
Primary: Visual-analogue Pain Scale — 6; 4 units on a scale
N/A N=60 De-implementation of Low Value Castration for Men With Prostate Cancer
Cancer of Prostate
Primary: Feasibility - Site Level: Medical Center Director (MCD) Approval — 3; 1 sites
N/A N=178 Sexual Function and Wellbeing in Males With Rectal Cancer
Rectal Cancer
Primary: Change in Serum Testosterone Levels Between Baseline and After Preoperative Radiotherapy. — 11.3; 11.9; 9.3 nmol/L — p=0.014